DURHAM, N.C. --(BUSINESS WIRE)--Jan. 9, 2023-- Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate...